FWBI - First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference | Benzinga
BOCA RATON, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
In a prerecorded presentation, available on-demand to all registered conference attendees, Mr. Sapirstein will provide an overview of First Wave BioPharma's business and clinical development programs as well as anticipated milestones. During the conference, Mr. Sapirstein and members of the Company's senior management team will conduct one-on-one meetings with registered investors.
Details of the conference are as follows:
| Event: |